Your search for smoking cessation returned 23 results

The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.

Adverse events observed among adolescent smokers in the study were comparable to those seen in adult studies.

For current non-daily cigarette smokers, there were statistically significant associations with death from lung cancer, oral cancer, circulatory death, cardiovascular death, cerebrovascular death (stroke), and chronic obstructive pulmonary disease.

Benefits of smoking cessation medications decline over the first year.

The researchers analyzed the medical records of 56,851 new users of varenicline.

The data showed TNP was significantly more effective vs. no medication assisted quit attempts for males (odds ratio [OR] 1.37, 95% CI: 1.02, 1.83; P=0.03) but not for females (OR 0.96, 95% CI: 0.71, 1.31; P=0.82).

Researchers examined electronic records from one regional poison center for cases of intentional bupropion ingestion between January 1, 2009 to December 31, 2015. Reports that cited IV lipid emulsion administration or death as an outcome were further evaluated.

The researchers believe that based on their findings, e-cigarette smokers may be at increased risk for bladder cancer.

The FDA determined the benefits of this smoking cessation therapy outweighed the potential risks.

In a first-ever prospective study evaluating lorcaserin in reducing post-cessation weight gain in overweight and obese smokers, researchers found that lorcaserin combined with varenicline minimized weight gain and increases in waist circumference.